Search

Ipsen SA.

Atidarymo kaina

SektoriusFinansų sektorius

151.1 -1.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

149.4

Max

153.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

294M

403M

Pardavimai

334M

2.2B

P/E

Sektoriaus vid.

24.013

19.138

Dividendų pajamingumas

1.07

Pelno marža

18.405

Darbuotojai

5,535

EBITDA

556M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+12.21% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

1.07%

4.76%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-888M

12B

Ankstesnė atidarymo kaina

152.41

Ankstesnė uždarymo kaina

151.1

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-26 23:56; UTC

News

Principal Financial Group reports Q3 net income of $631.9 million, but adjusted EPS of $2.22 missed estimates, contributing to after-market declines.

2026-10-26 23:56; UTC

News

Piper Sandler initiates coverage on HF Sinclair Corp with an Overweight rating, reflecting a positive outlook for the company.

2026-10-26 23:51; UTC

Social Media
News

Robinhood shares are modestly higher in after-market trading following Bernstein's forecast of $1.7 billion in annual revenue from prediction markets by 2028.

2026-10-26 23:51; UTC

Correlated Moves
News

Bank of Hawaii Corp was reiterated as a "Buy," trading modestly higher in after-market hours, alongside 1st Source Corp's advance.

2026-10-26 23:51; UTC

Social Media
News

Nucor Corp reported third-quarter earnings of $1.32 billion, with adjusted EPS of $4.84 missing consensus estimates, leading to a modest after-market decline.

2026-10-26 23:51; UTC

News

Amgen Inc appoints David W. Gibbs to its Board of Directors, effective immediately, to serve on the Audit and Compensation Committees.

2026-10-26 23:46; UTC

News

Northeast Bank reported Q1 earnings of $3.42 per share, missing estimates, with revenues of $64.27 million also falling short of expectations.

2026-10-26 23:42; UTC

Social Media
News

Meta Platforms Inc launches a new video platform called Features on Instagram, allowing creators to publish videos of up to 90 minutes.

2026-10-26 23:41; UTC

Social Media
Correlated Moves
News

Applied Materials Inc increases its stake in BE Semiconductor Industries to approximately 20%, enhancing collaboration in hybrid bonding technology and advanced chip packaging.

2026-10-26 23:41; UTC

News

Fortis Inc is down in after-market trading, having retraced from an early peak to nearly 1% below Monday's close ahead of its Q3 2026 results.

2026-10-26 23:41; UTC

News

Range Resources shares declined modestly in after-market hours following its all-stock acquisition agreement with EQT, which aims for $325 million in annual cost savings.

2026-10-26 23:41; UTC

News

Zeta Global Holdings Corp will release its Q3 2026 financial results on November 9, 2026, with a conference call featuring CEO David A. Steinberg.

2026-10-26 23:36; UTC

News

Huntington Ingalls Industries Inc is trading modestly lower in after-market hours, settling at a loss of approximately three-quarters of a percent following Monday's close.

2026-10-26 23:31; UTC

Correlated Moves
News

Lumentum Holdings Inc shares are higher in after-market trading, bolstered by a Buy rating from StoneX and a price target of $1.2K.

2026-10-26 23:31; UTC

Social Media
News

Tesla's stock advanced in after-market hours after Barclays upgraded it to "overweight," citing merger expectations with SpaceX and growth potential in its automotive business.

2026-10-26 23:31; UTC

Social Media
News

Dollar General faces a lawsuit from the FTC and 20 states over alleged deceptive pricing practices, following over 29k consumer grievances.

2026-10-26 23:31; UTC

News

Arcos Dorados Holdings Inc shares are trading higher in after-market hours, recovering from earlier declines amid volatility in Brazilian equities and concerns over fiscal discipline.

2026-10-26 23:21; UTC

Correlated Moves
News

Orrstown Financial Services ranks 77th on Fortune's 2026 Fastest-Growing Companies list, the highest among banks in Pennsylvania or Maryland.

2026-10-26 23:21; UTC

News

Arcus Biosciences grants options for 10.65k shares and restricted stock units for 5.35k shares under its 2020 Inducement Plan, contributing to stock's decline.

2026-10-26 23:16; UTC

Event
News

Dorman Products Inc reported Q3 adjusted EPS of $2.08, exceeding estimates, but revenue of $561.7 million fell short of consensus, prompting lowered guidance.

2026-10-26 23:11; UTC

News

Kinder Morgan Inc shares are trading modestly higher in after-market hours following the announcement of $5.4 billion in new infrastructure projects to expand its natural gas network.

2026-10-26 23:11; UTC

Correlated Moves
News

Wolfe Research initiates coverage on Fifth Third Bancorp with an Outperform rating, contributing to the stock's modest gains in after-market trading.

2026-10-26 23:11; UTC

Macro News
News

Bitmine has acquired 10.45k ETH, raising its total holdings to 6.05M ETH, which represents 4.95% of the total supply.

2026-10-26 23:06; UTC

Correlated Moves
Social Media
News

Broadcom secures a $63 billion financing deal with Bank of America, Blackstone, Citigroup, and Morgan Stanley to support AI chip purchases for Anthropic PBC.

2026-10-26 23:06; UTC

Social Media
News

Welltower reports Q3 net income of $415 million and EPS of $0.54, missing expectations, while revenue of $3.72 billion exceeds forecasts.

2026-10-26 23:06; UTC

Correlated Moves
News

S&P Global Ratings upgraded Synopsys Inc's credit rating to 'BBB+' from 'BBB', citing strengthened operating momentum and increased revenue growth forecasts through 2029.

2026-10-26 23:02; UTC

Social Media
News

Whirlpool Corporation reported a third-quarter net loss of $249 million, cutting its full-year GAAP EPS guidance to -$4.95 from $2.25-$2.75.

2026-10-26 23:02; UTC

Social Media
News
Event

Rambus reports record Q3 revenues of $218.3 million and adjusted EPS of $0.84, but conservative Q4 guidance leads to a decline in after-hours trading.

2026-10-26 23:01; UTC

News

Cleveland-Cliffs' subsidiary Stelco confirms compliance with all 34 undertakings related to its acquisition under the Investment Canada Act, exceeding employment commitments.

2026-10-26 23:01; UTC

News

Greenbrier Companies reported Q4 adjusted EPS of $0.39, missing estimates of $0.76, and provided FY 2027 guidance below consensus, contributing to after-market declines.

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

12.21% į viršų

12 mėnesių prognozė

Vidutinis 170 EUR  12.21%

Aukščiausias 235 EUR

Žemiausias 130 EUR

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

1

Pirkti

1

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat